ABUS
$3.08
Arbutus Biopharma Cp
$.16
5.48%
ABUS
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.20)
Revenue:  $1.81 Mil
Friday
Nov 6
7:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ABUS reports earnings?
Beat
Meet
Miss

Where is ABUS's stock price going from here?
Up
Flat
Down
Stock chart of ABUS
Analysts
Summary of analysts' recommendations for ABUS
Score
Grade
Pivots
Resistance
$3.38
$3.26
$3.17

$3.05

Support
$2.96
$2.84
$2.75
Tweet
Growth
Description
Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC.